Currently, the solution to gemcitabine resistance in pancreatic cancer is to bypass the NTs and dCK through different mechanisms or drug modifications, thereby enhancing the transport and phosphorylation of gemcitabine. The gene discussed is DCK; the disease is familial pancreatic carcinoma.